Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | LGMN | Q99538 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15269613 | 0.81 | LMNA (0.63) | ALDH1A1LMNAKDM4ESMN1; SMN2GAA | |
| SCHEMBL25226269 | 0.76 | LGMN (0.50) | ALDH1A1LMNAKDM4ELGMNSMN1; SMN2 | |
| SCHEMBL17305205 | 0.75 | POLB (0.42) | ALDH1A1LMNAKDM4ELGMNSMN1; SMN2 | |
| SCHEMBL3919469 | 0.75 | ADRB2 (0.55) | ALDH1A1LMNAKDM4E | |
| SCHEMBL15010070 | 0.75 | SRPK1 (0.45) | ALDH1A1LMNAKDM4ESMN1; SMN2TSHR | |
| SCHEMBL22053011 | 0.74 | LGMN (0.44) | ALDH1A1LMNAKDM4ELGMNSMN1; SMN2 | |
| SCHEMBL17305245 | 0.74 | ALDH1A1 (0.40) | ALDH1A1LMNAKDM4ESMN1; SMN2TSHR | |
| SCHEMBL17305218 | 0.72 | LMNA (0.46) | ALDH1A1LMNAKDM4ESCN9ATSHR | |
| SCHEMBL18608805 | 0.72 | ALDH1A1 (0.39) | ALDH1A1LMNAKDM4EFFAR4SMN1; SMN2 | |
| SCHEMBL30112359 | 0.71 | LGMN (0.42) | ALDH1A1LMNAKDM4ELGMNSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3150578-B1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-10-14 | — | — | EP | disclosed |
| US-9981960-B2 | Pyrrolidine compound and application as melanocortin receptor agonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-29 | — | — | US | disclosed |
| US-20170190697-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-07-06 | — | — | US | disclosed |
| US-20170190697-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190697-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MC1R, MC5R, MC3R | ALDH1A1 1837/4885LMNA 4726/4885KDM4E 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.